Emergent BioSolutions (EBS) $1.6B BARDA Contract 'Very Positive' - Wells Fargo's Maris

September 30, 2016 10:33 AM EDT
Get Alerts EBS Hot Sheet
Price: $29.92 -0.27%

Rating Summary:
    8 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 13 | Down: 22 | New: 54
Trade EBS Now!
Join SI Premium – FREE

News and research before you hear about it on CNBC and others. Claim your 2-week free trial to StreetInsider Premium here.

Wells Fargo analyst David Maris called today's news from Emergent BioSolutions (NYSE: EBS) of a $1.6 billion BARDA contract opportunity for the development and ultimate procurement NuThrax, EBS's next generation anthrax vaccine, "very positive."

The FDA could authorize NuThrax under the Emergency Use Authorization mechanism as early as late-2018.

Maris notes the BARDA contract includes procurement options for an additional 7.5 million to 50 million doses of NuThrax for the Strategic National Stockpile, representing an opportunity for EBS of $255 million on the low end and up to $1.4 billion on
the high end.

"On the high end, this represents an estimated price per dose of approximately $28, which is above our expectation for $25 per
dose," he said.

He added, "We see the award and announcement today as a confirmation of our expectations, and good execution by EBS when needed. Finally, we see this as a confirmation that the U.S. government has not shifted its priority for biodefense of anthrax countermeasures, as some had feared."

The firm reiterated an Outperform rating and $40-$42 valuation range.

For an analyst ratings summary and ratings history on Emergent BioSolutions click here. For more ratings news on Emergent BioSolutions click here.

Shares of Emergent BioSolutions closed at $27.76 yesterday.

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, FDA, Hot Comments

Related Entities

Wells Fargo, David Maris

Add Your Comment